Potential mechanisms of cancer prevention by weight control by Jiang, Yu & Wang, Weiqun
POTENTIAL MECHANISMS OF CANCER PREVENTION BY WEIGHT 
CONTROL 
Yu Jiang 
Department of Human Nutrition, Kansas State University, 
Manhattan, KS 66506, USA 
yjiang@ksu.edu 
Weiqun Wang* 
Department of Human Nutrition, Kansas State University, 
Manhattan, KS 66506, USA 
wwang@ksu.edu 
*Correspondence at:  Phone: 1-785-532-0153; Fax: 1-785-532-3132; Email: wwang@ksu.edu 
Received July 17, 2008 
Revised July 25, 2008 
Weight control via dietary caloric restriction and/or physical activity has been demonstrated in 
animal models for cancer prevention. However, the underlying mechanisms are not fully understood. 
Body weight loss due to negative energy balance significantly reduces some metabolic growth 
factors and endocrinal hormones such as IGF-1, leptin, adiponectin, and glucocorticoids, etc., that 
may be associated with anti-cancer mechanisms. In this review, we summarized the recent studies 
related to weight control and growth factors. The potential molecular targets focused on those 
growth factors- and hormones-dependent cellular signaling pathways are further discussed. It 
appears that multiple factors and multiple signaling cascades, especially for Ras-MAPK-
proliferation and PI3K-Akt-anti-apoptosis, could be involved in response to weight change by 
dietary calorie restriction and/or exercise training. Considering prevalence of obesity or overweight 
that becomes apparent over the world, understanding the underlying mechanisms among weight 
control, endocrine change and cancer risk is critically important. Future studies using "-omics" 
technologies will be warrant for a broader and deeper mechanistic information regarding cancer 
prevention by weight control.  
Keywords: Weight Control; Dietary Calorie Restriction; Physical Activity; IGF-1, Leptin, 
glucocorticoids, Cancer Prevention. 
1.   Introduction 
Obesity rate in the U.S is growing rapidly during the past 20 years (CDC, 2006). It has 
become a serious world wide problem which is associated with increased risk for several 
chronic diseases, including cancer, diabetes, and cardiovascular disease. Studies showed 
evidence for a positive association between overweight/adiposity and cancer risk in 
esophagus, pancreas, colon, rectum, endometrium, kidney, and postmenopausal breast 
cancer (WCRF/AICR, 2007). Weight control, therefore, has become an important 
strategy against cancer and/or other chronic diseases. Body weight control is carried out 
by the balance of negative energy, which is tightly associated with dietary calorie intake 
and/or physical activity (energy expenditure). A positive energy balance, via increased 
dietary intake and/or decreased energy expenditure, results in increased weight and fat 
mass, or adiposity. Negative energy balance via decreased calorie intake or increased 
expenditure in adult may help maintain body weight and thus benefit health status.  
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Calorie restriction is referred to decrease of energy intake without malnutrition. In calorie 
restriction regimens, proteins and all the essential micronutrients such as vitamins and 
minerals are kept same. Only the total amount of energy from fat and carbohydrate is 
reduced usually at 20-40% of the ad libitum-fed controls. The cancer preventive effect of 
caloric restriction has been found for almost one hundred years. The first animal study 
was done as early as 1909 by Moreschi, who observed that tumors transplanted into 
underfed mice grew slower than those in ad libitum fed mice (Moreschi et al., 1909). In 
the 1940s, Tannenbaum and colleagues found that reduced food intake decreased tumor 
incidence in experimental animals (Tannenbaum et al., 1947). Later on, the preventive 
effect of calorie restriction on cancer is confirmed in various animal models such as 
primate and rodent or various organs including mammary gland, prostate, colon, and 
skin. Calorie restriction has been shown to be effective in both spontaneously occurring 
and chemically induced cancers. Calorie restriction is also able to lessen cancer in 
genetically engineered models, e.g., p53 knock out mice and APC min mice (Hursting SD, 
1997; Mai V et al., 2003). To data, calorie restriction is found to be the most potent and 
effective dietary intervention strategy for cancer prevention in animal models (Hursting 
SD. et al., 2003). 
The health benefit of physical activity (exercise), on the other hand, has been known for 
many decades. Accumulated evidence both in human studies and animal models has 
shown that physical activity is helpful in decreasing cancer risk. The epidemiologic 
studies on the relationship between physical activity and cancer prevention as reviewed 
by Friedenreich and Orensterin (2002) suggested that the evidence of cancer prevention 
by physical activity be convincing for colon and breast cancer, probable for prostate 
cancer, and possible for endometrium and lung cancer, although some other types of 
cancers seemed less sufficient and conclusive. Colon cancer is studied most with respect 
to physical activity in animal models. It was found that physical activity, both by forced 
treadmill and voluntary wheel, was effective in reducing azoxymethane-induced colon 
carcinomas in rats (Reddy BS et al., 1988; Thorling EB et al., 1994). However, the results 
were not conclusive in APC min mice (Basterfield et al., 2005). The effect of physical 
activity on breast cancer prevention in animal models was reviewed by Thompson et al. 
(2004), indicating physical activity might inhibit mammary carcinogenesis, but the effect 
was less reproducible compared to calorie restriction. Overall, the impact of physical 
activity on cancer prevention is positive, but not consistent or potent as calorie restriction 
approach.  
Despite many studies have been conducted, no mechanism of weight control on cancer 
prevention has been well-established. Enhancement of DNA repair and diminution of 
oxidative damage to DNA, as well as reduction of oncogene expression have been 
postulated. Weight loss, via calorie restriction and/or exercise, has been found to reduce 
certain circulating growth factors and hormones, such as IGF-1, adipocytokins, 
glucocorticosteroids, which are critical in maintenance of cellular growth, proliferation, 
cell cycle, and apoptosis function. Reduction of these growth factors and inhibition of 
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these factors-dependent biological processes by weight control may contribute to the 
overall anti-carcinogenesis.  
2.    IGF-1: a key modulator for cell growth and anti-apoptosis 
2.1.   IGF-1 system: IGF-1, IGF-1 binding proteins, IGF-1 receptor and IGF 
signaling 
Insulin-like growth factors (IGF-1 and IGF-2) are 70-amino-acid polypeptides that have 
high sequence similarity to insulin. Both IGF-1 and IGF-2 have metabolic functions, and 
play important roles in cellular proliferation and differentiation. The major function of 
IGF-2 seems related to embryonic growth and early development (DeChiara et al., 1990), 
but IGF-1 is more important in post-natal growth. The synthesis of IGF-1 is mainly 
regulated by growth hormone in liver. IGF-1 is majority produced in the liver but also all 
the other cells. 
The circulating levels of IGF-1 and their bioavailability are modulated by a family of IGF 
binding proteins (IGF-BPs), which have six homologies. IGF-BP3 is the most abundant 
in humans. It is found that about 90% of IGF-1 in the serum is binding to IGFBP3, a 
complex formed that is very large and can not transport out of bloodstream. Free IGF-1 
or IGF-1 that binds to IGF-BP1 and IGF-BP2 are able to across the capillary endothelium 
and reach target tissues (Voskuil et al., 2005). IGF-BPs are degraded by proteases both in 
the tissues and in the circulation, through which IGF-1 is freed and interacts with IGF-1 
receptors. Furthermore, IGF-BPs can also modulate the process of IGF-1 binding to 
receptors and the IGF signaling (Holly et al., 1993; Clemmons, 1993).  
IGF-1 receptor (IGF-1R) is a member of receptor tyrosine kinase super family. IGF-1R 
binds IGF-1 with the highest affinity, while it can also bind IGF-2 and insulin (Ullrich et 
al., 1986).  In addition to IGF-1R, insulin receptor (IR) and IGF-2 receptor (IGF-2R) are 
able to bind IGF-1, but with less affinity. Studies showed that insulin receptor and IGF-1 
receptor could form heterohybrid (Soos et al., 1993; Pandini et al., 2002). 
Binding of IGF-1 to the receptors will induce autophosoporylation and activation of 
downstream signal network, such as phosphatidylinositol-3-kinase (PI3K) pathway.  The 
phosphorylation of PI3K results in activation of Akt. Activated Akt will then inhibit the 
activation of interleukin-1β-converting enzyme (ICE)-like protease, therefore suppresses 
apoptosis. Binding of IGF-1 to its receptor is also found to activate other pathways, such 
as MAPK pathway. Activation of MAP kinase will lead to increase of cell proliferation 
(Raushan et al., 2006).  
2.2.    IGF-1 and cancer  
The IGF-1 system has been found to be involved in human development and the 
maintenance of a normal function and homeostasis of the cell growth in the body. 
Abnormal function in increased IGF-1 levels leads to break down of normal cell 
homeostasis and function, which usually found in cancer development. Studies showed 
that the neoplasia process may due to the elevation of IGF-1 in the circulation and/or the 
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increased sensitivity of IGF-1R to the hormone. Increased IGF-1 stimulates cell 
proliferation and inhibited apoptosis in various cancer cells. The relationship of IGF-1 
and cancer and the potential corresponding mechanism have also been studied 
extensively in human subjects and animal models.  
In the study of colon cancer, it was found that the gene expression of IGF-1 was elevated 
in colon carcinomas (Tricoli et al., 1986).  Similar results were also found in the human 
breast and lung tumors (Yee et al., 1989). Later on epidemiological studies showed 
plasma IGF-1 levels were positively associated with higher risk of cancer, especially 
prostate and breast cancer. Chan et al. (1998) first demonstrated a link between 
circulating IGF-1 and prostate cancer risk using a nested case-control study. The study 
showed that plasma IGF-1 levels were positively associated with prostate cancer risk. 
Comparing to men in the lowest quartile of plasma IGF-1 levels, men in the highest 
quartile had a 4.3 folder higher risk of prostate cancer (Chan et al., 1998). In women, 
IGF-1 was found to be positively associated with pre-menopausal breast cancer rather 
than post-menopausal breast cancer (Renehan et al., 2004 lancet; Voskuil et al., 2005a; 
Canzian et al., 2006). The correlation between circulating IGF-1 levels and cancer risk 
was also found in colon cancer and bladder cancer (Giovannucci et al., 2001; Zhao et al., 
2003). In addition to cancer risk, elevated plasma IGF-1 was associated with benign 
prostatic hyperplasia, proliferation of colorectal mucosa, and colorectal adenomas 
(Khosravi J et al., 2001; Chokkalingam AP et al., 2002; Cats A et al., 1996; ReneHan AG 
et al., 2001; Teramukai S et al., 2002). Overall, the reported studies support that relatively 
high circulating IGF-1 levels may have a causal role in cancer development.  
IGF-1 and IGF-1 signaling are also found to play an important role in skin cancer. Rho et 
al. (1996) found that the mRNA level of IGF-1 and IGF-1 receptor in dermal and 
epidermal of mouse skin was significantly increased in the skin papillomas and 
carcinomas. In order to detect the potential role of IGF-1 signaling in the multistage 
mouse skin carcinogenesis, DiGiovanni lab developed transgenic mice HK1.IGF-1,  in 
which IGF-1 is over expressed in epidermis driven by a human keratin 1 promoter (Bol 
DK et al., 1997). The authors found that HK1.IGF-1 transgenic mice were more sensitive 
to tumor promoters such as TPA, chrysarobin, okadaic acid, and benzyl peroxide after 
initiated by DMBA than wild type mice. Comparing to wild type animals which received 
the same dose of carcinogen treatment, transgenic mice developed tumors more rapidly 
and the number of tumors per mouse were dramatically increased (Bol DK et al., 1997; 
Wilker E et al., 1999). In addition, squamous papillomas and carcinomas were found to 
developed spontaneously in a similar transgenic mouse model BK5.IGF-1, which over 
expresses IGF-1 in the basal layer of skin epidermis (DiGiovanni et al., 2000). Activation 
of IGF-1 receptor, epidermal hyperplasia and increased labeling index were also observed 
in these mice. Not only in chemically induced skin carcinogenesis, an altered IGF system 
were also found to contribute to HaCaT keratinocyte UV susceptibility (Thumiger et al., 
2005). The above data suggested that constitutive expression of IGF-1 and activation of 
IGF-1 receptor signaling pathways in basal epithelial cells lead to tumor promotion, in 
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which IGF-1 played an important role in skin cancer development. More recently, it was 
found that PI3K/Akt pathway is important in IGF-1 mediated skin promotion (Wilker et 
al., 2005). Inhibition of PI3K activity significantly blocked epidermal proliferation, as 
well as skin tumor development in DMBA initiated IGF-1 transgenic mice (Wilker et al., 
2005).  
2.3.   IGF-1 as a mediator in cancer prevention by weight control  
As discussed above, the high IGF-1 levels seem associated with the risk of cancer 
development and lowering IGF-1 levels via weight control appears to be related to a 
decreased cancer incidence. Thus, manipulating plasma IGF-1 levels have been applied 
in cancer prevention strategies.  In order to test this hypothesis, a mouse model that has a 
genetic deletion of liver IGF-1 gene was generated (Wu Y et al., 2003). In these mice, 
IGF-1 levels are 25% of that in none transgenic mice. Lowering circulating IGF-1 
significantly delayed mammary gland tumor development by carcinogen DMBA or C3 
(1)/SV40 large T- antigen induced carcinogenesis (Wu Y et al., 2003). Fibroblasts 
lacking IGF-1 receptor were found to be highly resistant to transformation by simian 
virus 40 T antigen (Pietrzkowski Z et al., 1992; Sell C et al., 1993). Moore et al. (2008) 
found that the activation of the Akt and mTOR signaling pathways by tumor promoter 
TPA were significantly reduced in IGF-1 deficient mice, resulting a blockage of 
epidermal response to tumor promotion. Kari et al. (1999) found that the functional 
disruption of IGF-1R markedly inhibited breast cancer metastasis in the nude mice by 
suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, 
lymph nodes, and lymph vessels. 
Reducing plasma IGF-1 by weight control has been investigated in a number of studies. 
Ruggeri et al. (1989) first reported that dietary calorie restriction decreased serum IGF-1 
significantly at the first and third week after the experiment started in female Sprague-
Dawley rats. Hursting et al. (1993) found serum IGF-1 in 40% of calorie restricted rats 
was only 44% of ad libitum fed controls. The author also infused human recombinant 
IGF-1 back to the dietary restricted rats by using osmotic minipumps. Infusion of IGF-1 
restored cell proliferation activity and enhanced mitogen responsiveness in dietary 
restriction treated rats (Hursting et al., 1993). In a tumor study of p53 deficient mice, 
20% of calorie restriction decreased circulating IGF-1 by 26% and restoration of IGF-1 in 
calorie restricted mice did not change the tumor incidence significantly, but increased cell 
proliferation and inhibited apoptosis dramatically (Dunn et al., 1997). Study by 
Thompson also found that 40% of calorie restriction reduced circulating IGF-1 by half in 
rats and restoration IGF-1 failed to have effect on mammary tumor incidence (Zhu et al., 
2005). Studies in our lab also found that IGF-1 was significantly decreased by dietary 
calorie restriction and restoration of IGF-1 significantly abolished PI3K reduction in 
treadmill exercised mice with limited feeding at same amount as sedentary control (Xie et 
al., 2007). Overall, the above results showed that reduction of IGF-1 levels and thus 
down-regulation of IGF-1 signaling pathways as a consequence of dietary restriction 
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could contribute to anti-tumorigenesis. Restoration of IGF-1 abrogated, at least in part, 
the protective effect of calorie restriction on carcinogenesis. 
The impact of physical activity on IGF-1 reduction and cancer prevention is complicated. 
As reviewed by Kaaks et al. (2004), physical activity decreased IGF-1 level in children 
and adolescents. But for adults, the plasma IGF-1 levels were not decreased either by 
short bout exercise or physical training. Studies showed that weight control by long term 
exercise could decrease IGF-1. For example, a recent published paper found that plasma 
concentrations of IGF-1 were significantly lower in endurance runners than sedative 
controls (Fontana et al., 2006). In animal model, our lab found that exercise alone with ad 
libitum feeding was not sufficient to decrease plasma IGF-1 levels. When the exercised 
mice was fed with a same amount as their sedentary counterpart, plasma levels of IGF-1 
were modestly but significantly reduced (unpublished data). Nevertheless, the evidence 
by ours and others indicate a negative energy balance appears to be a fundamental 
requirement for IGF-1 reduction and potential cancer prevention.  
3.   Adipocytokines: a linkage of adipose and cancer risk 
Adipocytokines are secretary products of adipose tissue and have metabolic and 
endocrine functions. They include leptin, adiponectin, resistin, and visfatin, etc., which 
have been identified and studied recently for a potential relationship between obesity and 
cancer risk (Korner et al., 2005).  
3.1.   Leptin 
Leptin gene, which is also called obese (ob) gene, encodes a 16 kDa protein (Zhang et al., 
1994). As an adipocytokine, leptin is secreted mainly by adipose tissue. Other tissues, 
such as placenta, ovaries, skeletal muscle, pituitary gland, stomach, and liver, are also 
able to produce leptin. The major factor that affects circulating leptin levels is adipose 
tissue mass (Maffei et al., 1995). Increased body weight has been shown to be positively 
associated with high level of plasma leptin (Frederich RC et al., 1995). Leptin was found 
to regulate appetite and control body weight through affecting the hypothalamus, 
suppressing food intake and stimulating energy expenditure (Muoio et al., 2002). In 
addition to the central cirtuits, leptin also has effects in the periphery tissues, such as 
lung, intestine, skin, stomach, heart and other organs, though binding to leptin receptors 
(Margetic et al., 2002; Cornish et al., 2002).  
Leptin receptors contain extracellular, transmembrane and intracellular domains. The 
extracellular domain is responsible for leptin binding and intracellular domain recruits 
and activates downstream substrates. Activation of leptin receptors was found to 
stimulate signaling pathways, such as JAK2/STAT3, Ras/ERK1/2 and PI3K/Akt/GSK3. 
Other signaling proteins induced by leptin were also found, including protein kinase C, 
p38 kinase, and AP-1 component c-fos, c-jun, and junB, etc. (reviewed by Garofalo et al., 
2006).  
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Leptin is important in the regulation of energy balance. Obese (ob/ob) mice, which have 
leptin gene mutation, are found to be morbidly obese, infertile, hyperphagic, 
hypothermic, and diabetic (Huang et al., 2000). Infusion of recombinant leptin into these 
mice reduced food intake and decreased body weight (Campfield et al., 1995; Halaas et 
al., 1995). In diet induced obese mice, the circulating leptin was significantly elevated 
with the increase of body weight.  Studies also showed these mice are resistant to 
peripherally administrated leptin (Van Heek et al., 1996). Compared to normal weight 
people, obese people usually developed hyperleptinemia and leptin resistant, which might 
due to a defect in transporting of leptin through the blood barrier (Banks et al., 1996; 
Caro et al., 1996).  
Epidemiologic studies showed that moderately elevated serum leptin was associated with 
prostate cancer development (Stattin et al., 2001). People that have high leptin levels tend 
to have a large tumor (Chang et al., 2001, Saglam et al., 2003). However, some studies 
found there was no relationship between circulating leptin and prostate cancer risk 
(Lagiou et al., 1998; Stattin et al., 2003). In vitro, leptin is found to be a promoter in 
cancer cells.  Studies showed that leptin induced cell proliferation in breast cancer ZR75-
1 and HTB-26 cells via the activation MAPK and PI3K (Frankenberry et al., 2006). 
Leptin also simulated estrogen synthesis by increasing aromatase gene transcription and 
protein activity, which implied that leptin might be responsible for the resistance to anti-
estrogens during hormonal treatment of breast cancer (Sulkowska et al., 2006). In colon 
cancer cells, leptin induced cell growth and blocked apoptosis of human cancer HT29 
cells via stimulation of ERK1/2 and NFκB pathway (Hardwick et al., 2001; Liu et al., 
2001). In addition, the mitogentic activity of leptin has also been demonstrated in 
prostate, pancreatic, ovarian and lung cancer cells. Taken together, leptin seems to be 
important in tumor progression. Manipulation of plasma leptin might be effective in 
cancer prevention and treatment.  
As discussed above, leptin was positively associated with body weight and body mess 
index. Weight control seems to be effective in lowering circulating leptin.  Fontana et al 
(2006) showed that plasma concentrations of leptin were significantly lower in endurance 
runners than sedative controls. In animal models, it was found that 40% of calorie 
restriction significantly decreased the serum leptin levels in APCmin mice compared to the 
control (Mai et al., 2003). Studies by our laboratory showed that the plasma level of 
leptin was significantly decreased in calorie restricted mice and exercised mice with 
paired feeding, but not in exercised mice with ad libitum feeding (Xie et al., 2007).  
Interestingly, we found that leptin in subcutaneous fat cells was not affected by weight 
control treatment (Xie et al., 2007). All the above evidence suggests that leptin be 
important in medicating the cancer protective effects of weight control. Further research 
is needed to characterize the specific role of leptin in cancer development. 
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3.2.   Adiponectin 
Adiponectin is also an adipocytokine that is secreted in adipose tissue and plays an 
important role in obesity-related disorders. The gene of adiponectin is located on diabetes 
susceptibility locus chromosome 3q27 (Sonnenberg et al., 2004; Takahashi et al., 2000). 
Adiponectin was found to account for 0.01% of total plasma protein in human serum 
(Arita et al., 2002). It exists in several forms: trimers, hexamers, high molecular weight 
multimers (HMW), or globular form. HMW form was suspected to be the most bioactive 
form (Richards et al., 2006; Fisher et al., 2005).   
Two adiponectin receptors have been identified. The signaling downstream of 
adiponectin receptors is still under investigation. Miyazaki et al. (2005) found that 
different forms of adiponectin have distinct biological effects, which may be through 
differential activation of downstream signaling. 
Some evidence has showed that adiponectin is an insulin sensitizing hormone and may 
process anti-diabetic activities (Kantartzis et al., 2005). The blood level of adiponectin 
was found to be lower in obese people and was able to neutralization of LPS activity and 
anti-inflammation (Tsuchihashi et al., 2006; von et al., 2006). In addition, adiponectin 
was also found to be a modulator of lipid metabolism and might have preventive effect 
on cardiovascular disease. Kim et al. (2006) found that an increase of adiponectin 
concentrations or the maintenance of the higher levels was negatively associated with 
cardiovascular risk factors in nondiabetic CAD male patients, independent of adiposity 
and smoking status (Kim et al., 2006). 
The potential anticancer properties of adiponectin have been investigated both in 
epidemiological study and animal models. There are three case control studies showed 
that low serum adiponectin levels were associated with an increase risk of breast cancer 
in women (Miyoshi et al., 2003b; Chen et al., 2005; Kang et al., 2005a). In breast cancer 
patient, people who have low serum adiponectin levels tended to have more aggressive 
tumor (Miyoshi et al., 2003a). The inverse relationship between serum adiponectin and 
endometrial cancer risk was also identified by two case control studies in Italy and Grace, 
respectively (Dal et al., 2004; Petridou et al., 2003). Adiponectin was found to be lower 
in prostate cancer patient comparing to healthy controls the levels were negatively 
correlated with histologic grade and disease stage (Goktas et al., 2005). Studies by 
Ishikawa et al. (2005) showed that in gastric cancer patients, their plasma adiponectin 
levels were significantly lower than healthy controls. In addition, the plasma adiponectin 
was negatively associated with tumor size, depth of invasion and tumor stage in 
undifferentiated gastric cancer (Ishikawa et al., 2005). A prospective nested case-control 
study conducted by Wei et al. (2005) observed that men with low plasma adiponectin 
levels had a higher risk of colon cancer than men with higher adiponectin. However, one 
study reported adiponectin was not associated with colorectal cancer (Lukanova et al., 
2006). Overall, studies in human subjects provided some evidence that adiponectin could 
protect against certain type of cancer.  
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The cancer preventive effect of adiponectin may partially explained by its ability in 
modulating the biology of tumor cells. Studies by Yokota et al., (2000) found that 
adiponectin suppressed the growth of myelocyte cells, induced apoptosis in myelotye 
leukemia cells, and inhibited TNF-alpha production. Adiponectin was found to inhibit 
breast cancer MDA-MB-231 and MCF-7 cells proliferation and induce cell cycle arrest 
and apoptosis in these cells (Kang et al., 2005b; Dieudonne et al., 2006). Bub et al., 
(2006) reported that adiponectin suppressed the growth of prostate cancer cells. In colon 
cancer cells, however, Ogunwobi et al. (2006) demonstrated that adiponectin was a 
promoter of colon cancer HT29 cells. 
Studies showed that plasma adiponectin level was negatively associated with obesity, 
glucose and lipid levels, and insulin resistance (Bluher et al., 2006). Weight control 
through dietary calorie restriction and/or exercise seem to elevate plasma adiponectin, 
however, the results are not very conclusive. Studies showed calorie restricted rats had a 
high level of plasma adiponectin with reduced blood glucose, plasma insulin, and 
triglyceride levels when compared with ad libitum fed controls (Zhu et al., 2004). 
However, in a human study, the serum concentration of adiponection was not found to 
change in people after three weeks calorie restriction (Barnholt et al., 2005). For the 
effect of exercise, Jamurtas et al. (2006) showed that plasma adiponectin was not 
changed in people up to 48 hours post-acute exercis. Oberbach et al. (2006) reported that 
after four weeks of physical training, adiponectin levels was significantly increased in 
people who had type 2 diabetes. The changing of adiponectin levels was correlated with 
enhanced insulin sensitivity (Oberbach et al., 2006). Other adipocytokins, such as resistin 
and omentin, may also play a role in weight control-mediated cancer preventive effects, 
but their cellular and physiological function are still not clear (McTernan et al., 2006; 
Yang et al., 2006). 
4.   Other hormones related to cancer prevention by weight control  
4.1.   Insulin 
Insulin is an important hormone that regulates blood glucose level. In the liver, it 
promotes glycogen synthesis by stimulating glycogen synthase and inhibiting glycogen 
phosphorylase. In muscle and fat tissues, insulin induces uptake of glucose via increasing 
GLUT4 expression. Insulin is also functioned as a moderate mitogen. After binding to its 
receptor, insulin may activate signaling pathways via phosphorylation of the insulin-
receptor stubstarate-1, Akt, mitogen activated protein (MAP) kinase, and PI3K kinase 
(Rose et al., 1998; Finlayson et al., 2003). Therefore, insulin has been found to induce the 
growth of both normal and cancerous cells (Watkins L et al., Int. .Cancer 1990; 
Koenuma, M. et al., 1989; Bjork et al., 1993). Insulin also promotes the bioactivity of 
IGF-1 via either increasing the number of growth hormone receptors in the liver or 
reducing hepatic secretion of IGFBP1, which binds and inhibits the activity of IGF-1 
(Underwood et al., 1994; Powell et al., 1991). 
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Obesity or lack of physical activity is found to be a major factor inducing insulin 
resistance and further hyperinsulineamina. Epidemiological studies showed that increased 
plasma insulin was associated with a high risk of cancer (Kaaks R et al., 2000; Nilsen, TI 
et al., 2001). Dietary calorie restriction and/or regular exercise has been linked with a 
decreased plasma insulin in several studies (Zhu et al., 2005, Friedenreich et al. 2002, 
Giovannucci, E  et al., 2001).  It is noted that weight control via decreasing calorie intake 
or increasing energy expenditure can regulate glucose homeostasis and increase insulin 
sensitivity. 
4.2.    Glucocorticoids  
Glucocorticoid hormones are a class of steroid hormones. The major function of these 
hormones are involved in regulation of glucose metabolism, such as stimulation of 
gluconeogenesis in the liver, inhibition of glucose uptake in the muscle and adipose 
tissue, stimulation of fat breakdown in adipose tissue, and mobilization of amino acids 
from extrahepatic tissues. Glucocorticoids are also important in fetal development and 
have anti-inflammatory and immunosuppressive effects.  
Glucocorticoid hormones act though binding to intercellular glucocorticosteroid receptor. 
After binding with the hormone, the new formed receptor-ligand complex dissociates 
with heat shock proteins and then translocates into the nucleus, where it binds again to 
glucocorticoid response elements (GRE) and acts as a transcription factor. Glucocorticoid 
receptor usually works as a negative transcription factor, and it has been shown to inhibit 
the transcription of almost all immune system-related genes. In some cases, activated 
glucocorticoid receptor may interfere with other transcription factors, such as AP-1 and 
NFκB (Stöcklin et al., 1996; Subramaniam et al., 2003) that are crucial in the regulation 
of a number of genes involved in inflammation, differentiation, cell proliferation, 
apoptosis, oncogenesis, and other biological processes (Karin and Chang, 2001; Shaulian 
and Karin, 2001; Ghosh and Karin, 2002; Karin et al., 2002).  
In addition, glucocorticoid steroids are potential tumor inhibitors. Administration of 
hydrocortisone in the diet showed preventive effect on the promoting phase of skin 
carcinogenesis in the mice (Trainin, 1963). There are a number of studies shown that 
glucocorticoid steroids are elevated in calorie restricted animals (Pashko and Schwartz, 
1992; Yaktine et al., 1998).  Adrenalectomy was found to decrease plasma corticosterone 
levels and abrogate the preventive effect of dietary restriction on skin tumor development 
(Pashko and Schwartz, 1992; Stewart et al., 2005). Similar results were also observed in 
lung carcinogenesis but not in mammary gland tumors (Pashko and Schwartz, 1996; 
Jiang et al., 2004). When administrating corticosterone in adrenalectomized mice, the 
cancer preventive effects of calorie restriction on skin carcinogenesis were restored as 
shown by our previous publication from the Birt lab (Stewart et al., 2005). Overall, the 
published data indicate glucocorticoids may be critical mediators in cancer prevention by 
calorie restriction.  
5.   Molecular Targets of cancer prevention by weight control 
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5.1.   Effects on cellular processes 
It is well known that cancer arises due to the loss of a normal growth control. In normal 
tissues, cell growth and cell death are highly regulated and balanced. In cancer, this 
regulation is disrupted, which is either from increased cell proliferation or loss of 
programmed cell death, or both.  
The effect of calorie restriction on cell proliferation has been investigated in numerous 
studies. Lok et al. (1990) reported that 25% of calorie restriction decreased cell 
proliferation by 72% in mammary gland and 30-60% in skin, esophagus, bladder, and GI 
tract of female Swiss Webster mice. Pashko and Schwartz (1992) showed that 27% of 
food restriction suppressed TPA-induced epidermal [3H]-thymidine incorporation. In 
C57BL/6 ×C3HF1 mice, a murine strain that develops liver tumor spontaneously, 40% of 
dietary restriction was found to decrease cell proliferation significantly in the liver (James 
et al, 1994). Dunn et al. (1997) demonstrated that 20% of calorie restriction significantly 
inhibited BrdU incorporation in the bladders of p53 knock out mice. Restoration of IGF-1 
brought the cell proliferation back to the level of the control mice (Dunn et al., 1997). 
Comparing to ad libitum feeding, 30% of dietary calorie restriction significantly inhibited 
cell proliferation in carcinogen treated mouse skin (Fischer et al., 1998). Using a heavy 
water labeling, Hsieh et al. (2005) investigated a time-course of the effects of calorie 
restriction on cell proliferation rates in female C57BL/6J mice. It showed the 
proliferation rates of mammary epithelial cells and T cells were markedly reduced within 
2 weeks with calorie restriction regimen when compared to that of ad libitum fed mice. 
Two weeks after refeeding, the cell proliferation rates rebounded to the basal level (Hsieh 
et al., 2005). We found that the percentage of PCNA in skin epithelial cells was 
significantly lower in 20% of calorie restricted mice than ad libitum fed mice, as shown 
by immunohistochemistry staining (Xie et al., 2007). The percentage of the splenocyte in 
S phase was significantly reduced by 40% of calorie restriction in p53 knock out mice as 
well as wild type mice, as shown by Hursting et al. (1994). Studies in Thompson lab 
showed that cell cycle regulators, i.e., cyclin D1, cyclin E, cyclin-dependent kinase 
(CDK)-2, and CDK-4, were decreased by 40% of calorie restriction in rat mammal 
carcinomas, while cyclin-dependent kinase inhibitors (CKI), i.e., Kip1/p27 and Cip1/p21, 
increased (Zhu et al, 2003; Jiang et al, 2004). Overall, the effects of calorie restriction on 
cell proliferation are clear and reproducible in the animal models. For physical activity, 
studies in our lab found the cell proliferation rates of exercised mice with paired feeding 
had a lower rate than sedentary mice, but exercise with ad libitum feeding actually 
enhanced proliferative rates in epidermal cells, suggesting exercise alone without dietary 
calorie limitation might promote cellular proliferation and result in inconsistent impact on 
cancer protection (Xie et al., 2007). 
Programmed cell death or apoptosis is highly regulated by a series of arranged 
morphological and biochemical events (Adams, 2003). It is important for maintenance of 
tissue homeostatsis, embryo development, and immune defense. Defects in apoptosis are 
thought to play an important role in cancer development (Gerl and Vaux, 2005; Lossi et 
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al., 2005). Induction of apoptosis was observed in both normal liver and putative 
preneoplastic foci induced by hepatomitogen cyproerone acetate in dietary calorie 
restricted rats (Grasl-Kraupp et al, 1994). Dietary restriction was also found to induce 
apoptosis in the liver of C57BL/6 ×C3HF1 mice (James et al, 1994). Increased apoptosis 
was observed in the bladder preneoplasia of p-cresidine-treated p53-deficient mice by 
dietary calorie restriction (Dunn et al., 1997). In mammary gland, calorie restriction 
induced apoptosis in both premaglignant and malignant pathologies (Thompson et al., 
2004). Thompson et al., reported that apoptosis regulatory molecules, i.e., Bcl-2, Bcl-xl, 
and XIAP, decreased and Bax and Apaf-1 increased significantly in the mammary 
carcinomas of calorie restricted rats when compared with that of the control rats 
(Thompson et al, 2004). They also reported that the activities of both caspases-9 and 
caspases-3 were significantly induced and Akt phosphorylation was depressed by calorie 
restriction. The authors proposed that an induction of apoptosis by calorie restriction 
might be associated with its inhibitory effect on IGF-1 signaling. As for the physical 
activity, the research on apoptosis is sparse. Studies from our lab showed that caspase-3 
activity but not caspase-3 protein increased significantly in epidermis of dietary calorie 
restricted and treadmill exercised mice in comparison with the sedentary controls (Xie et 
al., 2007).  
Collectively, all these data above indicate that modulation of cellular processes including 
inhibition of cell proliferation and restoration of apoptosis, is a molecular target in weight 
control for cancer prevention. Figure 1 shows a proposed mechanism by which weight 
control may inhibit cancer development via inhibiting the cross-talk between hormone-
dependent and TPA-promoted signaling pathways, resulting in modulating cellular  
 
Fig. 1.  A proposed mechanism by which weight control may inhibit cancer development via inhibiting the 
cross-talk between hormone-dependent and TPA-promoted signaling pathways, resulting in modulating cellular 
proliferation and anti-apoptosis. 
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proliferation and anti-apoptosis. Weight loss reduces circulated growth factor and/or 
hormone levels such as IGF-1, leptin, adiponectin, and glucocorticoids, that thus 
inactivate TPA-induced signaling through hormone or growth factor-dependent cascades, 
e.g., Ras-MAPK and PI3K-Akt pathways. Finally, it may lead to an inhibition of TPA-
induced cellular proliferation and elimination of IGF-1- persuaded anti-apoptosis. 
5.2.   Reduction of oxidative stress  
Oxidative stress may injure cellular DNA, protein and lipids in the tissue. It is thus 
associated with ageing and many chronic diseases. In carcinogenesis, reactive oxygen 
and nitrogen species can attack DNA directly and induce DNA mutations. Oxidative 
stress also occurs by the reactive products of a peroxidation from various 
macromolecules, such as lipid peroxidation that may lead to protein and DNA 
modification. Cumulative evidence has been shown that long term calorie restriction in 
rodents extend maximum life span and decrease oxidative damage to DNA and proteins 
(reviewed by Richado Credilla et al., 2005). Qu et al. (2000) found that 60% of calorie 
restriction completely abolished the increased oxidative damage in cloribrate-induced 
mouse liver (Qu et al., 2000)  
5.3.   Other possible impact  
Calorie restriction may also interfere with the expression balance between oncogene and 
tumor suppressor gene directly. “Oncogenes refer to genes whose activation can 
contribute to the development of cancer” (Osborne et al., 2004). They are mutated 
versions from pro-oncogenes, which function in cell proliferation and differentiation. 
Over-expression of oncogenes usually causes out of control cellular growth. One of the 
most known oncogenes is Ras (Retrovirus-associated DNA sequences) family. Ras plays 
an important role in cell proliferation and can inactive tumor suppressors and promote 
cancer development (Fernandes et al, 1995). “Tumor suppressor genes refer to those 
genes whose loss of function results in the promotion of malignancy” (Osborne et al., 
2004). Typically, a normal function of tumor suppressor genes is to inhibit cellular 
proliferation. Mutations of these genes usually result in a loss of their growth inhibition 
ability, which in turn may favors of cellular proliferation. Some examples of well known 
tumor suppressor genes include p53, retinoblastoma susceptibility gene, Wilms' tumors, 
neurofibromatosis type-1, and familial adenomatosis polyposis coli, etc. Previous studies 
have demonstrated that food restriction may induce an over-expression of tumor 
suppressor gene p53 (Fernandes G et al, 1995). In the Brown-Norway rats fed with 
calorie restricted diet or ad libitum diet, Hass et al. (1993) found that pancreatic acinar 
cells from calorie restricted animals had a lower growth rate and less N-methyl-N'-nitro-
N-nitrosoguanidine (MNNG)-induced transformation. Calorie restriction derived cells 
showed decreased c-Ha-ras gene expression, lower rate of mutation of p53 tumor 
suppressor gene, and increased genomic methylations of DNA (Hass et al., 1993).   
DNA repair occurs in the normal mammalian cells to repair DNA damage caused by 
multiple factors including oxidative stress. It reported that dietary calorie restriction 
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enhanced DNA repair ability against DNA damage caused by UV exposure (Lipman et 
al, 1989; Weraarchakul et al, 1989).  Hursting et al. (1999) suggested that both calorie 
restriction and exercise could induce DNA repair pathway, therefore block the early stage 
of carcinogenesis. However, 30% of calorie restriction failed to activate DNA repair 
pathways and inhibit tumor development in the DNA mismatch deficient mice (Tsao et 
al, 2002). 
6.   Summary 
As we know more about the protective mechanisms of weight control, it is becoming 
apparent that it is not only one single mechanism involved. Most likely, it is a 
combination of multiple factors and multiple signaling pathways involved. Hundreds of 
biological molecules may cooperate in this network complex. Therefore, traditional 
molecular biology techniques seem not to meet the requirement to gain a broader and 
deeper overview of the mechanisms. Fortunately, recently developed technologies named 
“-omics” may provide us a chance to take a global view of these biological processes. 
The “-omics” techniques such as genomics, proteomics, and lipidomics, etc, usually 
present a profile change of gene, protein, and lipid expression, respectively. Microarray 
study is the first step to obtain a gene expression profile, together with proteomics and 
lipidomics may generate a clear picture of a profiling response to the weight loss 
treatment. Our on-going studies by using these state of the art technologies hopefully lead 
to a better and deeper mechanistic information regarding the established cancer 
prevention by weight control in the near future.  
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